Novo Nordisk · 17 hours ago
Internship - Chemical Biology
Lexington, MA
Internship
Onsite
Intern
$52K/yr - $89K/yrNovo Nordisk is a global pharmaceutical company focused on life science innovation. The Chemical Biology intern will participate in technological development activities related to a DNA-Encoded Library affinity screening platform, engaging in interdisciplinary experiments that encompass molecular biology techniques and protein sciences applications.
BiotechnologyHealth CareMedicalPharmaceutical
No H1B
Responsibilities
Participate in technological development activities and experiments relating to a DNA-Encoded Library (DEL) affinity screening platform
Conduct molecular biology techniques such as DNA gel electrophoresis, PCR amplification, DNA ligation, Next-Generation Sequencing sample preparation, DNA quantification, and DNA purification
Engage in protein sciences applications including protein characterization, protein immobilization, buffer composition, and protein-ligand interactions
Generate and optimize an SOP and/or collect sequencing data to inform future DEL library designs
Qualification
Required
Must be a current student enrolled at an accredited college or university pursuing at least a bachelor's degree
Strong academic record with a preferred cumulative GPA of 3.0 or higher
Conscientious self-starter with good organizational skills, project management skills and attention to detail
Ability to balance multiple projects and priorities, must be able to multi-task
Strong interpersonal communication and ability to collaborate with teams; must effectively operate independently, across functional lines, and with internal customers
Demonstrated personal initiative, self-motivation, flexibility, adaptability and willingness to learn
Proficient in Microsoft Office Tools including Word, Excel, PowerPoint, etc
Preferred
An in progress undergraduate or graduate degree in Chemistry, Biochemistry, Biology, or a related discipline preferred
Company
Novo Nordisk
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases.
Founded in 1923
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$22M2018-12-05Post Ipo Equity· $22M
1981-07-09IPO
Leadership Team
Lars Fruergaard Jørgensen
President and CEO
Lars Sorensen
President & CEO
Recent News
2026-02-09
Company data provided by crunchbase